about
Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling studySurgical mask to prevent influenza transmission in households: a cluster randomized trial.Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapyPopulation modeling of influenza A/H1N1 virus kinetics and symptom dynamicsA pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and controlEffects of aging on influenza virus infection dynamics.Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.Reply: To PMID 25098971.HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics.Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
P50
Q28537982-EDB52E77-3B8E-4B61-943D-DE74EC80192AQ30226877-59B0F060-2A84-4964-A0A3-EC9C530B510BQ30394336-71C89AFC-15B7-4729-821E-2DAAF866D90CQ34675037-FEC6CD34-317C-4354-8B2A-5B5995E78993Q34742833-DBA9F4F5-EDC6-4D61-B4A9-3EDBA228FF9AQ35449696-7677B38B-CAC5-4721-8A4B-791A6694B41BQ36428213-295EB1C1-4776-4FAA-A3B6-56C25842626DQ36889376-C36EF7A3-ACFD-41D8-AE79-2A87DDC6C18CQ37368417-217C4618-8013-4BCA-AE57-E34F961F1124Q37501314-95F83F56-2F8D-492D-AF98-3F454D0C8B00Q37713884-BBD95431-BF40-4F5F-84AB-96CA574C1F47Q40058939-044164BC-41F5-4340-9380-5BC810DBAECCQ40641829-48C1948E-0519-45F7-870A-30693B20E970Q42548764-8D1F4E08-E5B2-4ED2-AED3-25D970A30568Q47138788-CDE112FB-763E-4155-BF14-D1DF97F34956Q52639125-E32AF029-8B7A-4F6A-AB71-EAFE043B4F8FQ59349457-D26E2147-3B49-4094-AB43-2A6FE8F5394F
P50
description
researcher ORCID ID = 0000-0001-7643-1219
@en
wetenschapper
@nl
name
Laetitia Canini
@ast
Laetitia Canini
@en
Laetitia Canini
@es
Laetitia Canini
@nl
type
label
Laetitia Canini
@ast
Laetitia Canini
@en
Laetitia Canini
@es
Laetitia Canini
@nl
prefLabel
Laetitia Canini
@ast
Laetitia Canini
@en
Laetitia Canini
@es
Laetitia Canini
@nl
P106
P1153
6506547484
P31
P496
0000-0001-7643-1219